TY - JOUR T1 - Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2020-001701corr1 VL - 9 IS - 10 SP - e001701corr1 A2 - , Y1 - 2021/10/01 UR - http://jitc.bmj.com/content/9/10/e001701corr1.abstract ER -